Quantification of radiopharmkon concentration within the scitigraphis diagnostic via SPECT/CT (QRCS-1): a prospective data acquisition within clinical indicated examinations

Quantification of radiopharmkon concentration within the scitigraphis diagnostic via SPECT/CT (QRCS-1): a prospective data acquisition within clinical indicated examinations - QRCS/CT-1-BO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013571

Enrollment

500

Registered

2018-02-19

Start date

2015-04-22

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61 C78.7

Interventions

Group 1: Single-arm observational study: In this study the image datasets from clinical SPECT/CT examinations of patients will additionallly be revised with the new quantification methods. Thus, the c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: indication for SPECT/CT examination

Exclusion criteria

Exclusion criteria: pregnancy

Design outcomes

Primary

Measure	Time frame
Overall Survival over a period of 3 years Aims of the study: •Correlation of the radiotracer accumulation with manifestation of the disease in patients treated at the Department of Nuclearmedicine (i.g. SIRT in liver tumors, radionuclide therapy of osseous metastases in prostate cancer). In addition correlations with outcome of therapy and potential side effects will be investigated. •Influence of segmentation parameters of (CT-information, NM-image, Threshholds) on measured activity and distribution volume •Comparison of the results of phantom measurements in variation of Target-Background-ratio, lesion size and simulated tissue attenuation •Comparison with established semiquantitative analyses of the tracer uptake (i.g. Shunt assessment in SIRT simulation)	—

Measure

Time frame

Overall Survival over a period of 3 years Aims of the study: •Correlation of the radiotracer accumulation with manifestation of the disease in patients treated at the Department of Nuclearmedicine (i.g. SIRT in liver tumors, radionuclide therapy of osseous metastases in prostate cancer). In addition correlations with outcome of therapy and potential side effects will be investigated. •Influence of segmentation parameters of (CT-information, NM-image, Threshholds) on measured activity and distribution volume •Comparison of the results of phantom measurements in variation of Target-Background-ratio, lesion size and simulated tissue attenuation •Comparison with established semiquantitative analyses of the tracer uptake (i.g. Shunt assessment in SIRT simulation)

—

Secondary

Measure	Time frame
Progression-free survival over a period of 3 years	—

Countries

Germany

Contacts

Public ContactHelmut Dittmann

Radiologische UniversitätsklinikAbteilung Nuklearmedizin und Klinische Molekulare Bildgebung

nuklearmedizin@med.uni-tuebingen.de0049-(0)-7071-2986553

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026